Datum Källa Rubrik Typ Alternativ
2022-12-06 Redeye Redeye: Redeye Initiates Coverage of Enzymatica Analyser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica och University of Kent startar studie för att undersöka hur elitidrottare kan förebygga virusinfektioner i de övre luftvägarna Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 16 Nov 2022 | Enzymatica

Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes

Enzymatica has initiated a new study into the effect of ColdZyme on the upper respiratory resilience of competitive endurance athletes – a group to which viral protection is a key priority. The study is being undertaken by the University of Kent, UK, and builds on a previous 2020 study by the same research team, showing that ColdZyme reduces the duration and symptoms of common cold in endurance athletes (e.g. triathlon, marathon, cycling).

”ColdZyme’s ability to reduce the number of lost training days could play an important role for many endurance athletes. The previous study showed athletes who used ColdZyme had milder common cold symptoms and half as many lost training days as athletes in the control group. Our new study will further explore ColdZyme’s ability to allow endurance athletes a speedier recovery from common colds and other upper respiratory virus infections”, said Professor Glen Davison, Head of School of Sport and Exercise Sciences at University of Kent.

The first participants are enrolled this week, with the expectation that the full study will be presented next fall, before the cold season. The methodology is a double-blind, placebo-controlled clinical study, utilizing parallel groups design, in which participants will complete a daily training log and illness log according to the Jackson scale. Oropharyngeal swabs will be collected from both groups to identify virus strains causing the infections, as well as measuring viral load.

”We know that many groups that truly want to avoid common colds and other upper respiratory infections are great supporters of ColdZyme, be it teachers, kindergarten staff or endurance athletes. Enzymatica will launch a number of clinical trials to further investigate ColdZyme’s effect on viruses. So far, ColdZyme has been proven in vitro to block 11 different upper respiratory viruses, and we now aim to repeat these findings in vivo in clinical trials”, said Claus Egstrand, CEO of Enzymatica.

More information about the study: ISRCTN – ISRCTN18133939: Does ColdZyme mouth spray protect athletes against upper respiratory tract infection? ( https://www.isrctn.com/ISRCTN18133939 )

For more information, please contact:

Claus Egstrand, CEO, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com

 

Enzymatica AB develops and sells health products mainly to treat diseases and symptoms in the upper respiratory tract. The products are based on a barrier technology that includes marine enzymes with unique properties. The company’s first product is the medical device product ColdZyme®, a mouth spray for colds. The product has been launched in about 30 markets on four continents. The strategy is to continue to grow by developing more health products, strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.com.

2022-11-03 Penser Access Penser Access: Inte helt ute ur coronatunneln - Enzymatica Analyser Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Kvartalsrapport Q3/2022: En bredare roll för ColdZyme adderar potential för framtiden Rapporter Ladda ner | Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future Rapporter Ladda ner | Visa Stäng
2022-11-01 Enzymatica Enzymatica AB: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells Pressreleaser Ladda ner | Visa Stäng
2022-11-01 Enzymatica Enzymatica AB: Ny studie bekräftar: ColdZyme hindrar virus som orsakar Covid-19 från att fästa vid mänskliga luftvägsceller Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica announces outcome of new rights issue Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica offentliggör tilläggsprospekt Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica publishes supplementary prospectus Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme also blocks omicron variants BA.4 and BA.5 Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme blockerar även omikronvarianterna BA.4 och BA.5 Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Enzymatica Enzymatica AB: Prospekt avseende Enzymaticas företrädesemission offentliggjort Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Enzymatica Enzymatica AB: Publication of prospectus regarding Enzymatica's rights issue Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Penser Access Penser Access: Vändning i sikte - Enzymatica Analyser Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Kvartalsrapport Q2/2022: Förbättrad försäljning skapar tillförsikt Rapporter Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Interim report Q2/2022: Improved sales give confidence for the future Rapporter Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 74.7 million Pressreleaser Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 74,7 MSEK Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Enzymatica Enzymatica AB: ColdZyme blocks omicron virus - according to new research Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Enzymatica Enzymatica AB: ColdZyme blockerar omikronvirus - enligt ny forskning Pressreleaser Ladda ner | Visa Stäng
2022-06-16 Enzymatica Enzymatica AB: Enzymatica signs loan agreement with major shareholders Pressreleaser Ladda ner | Visa Stäng
2022-06-16 Enzymatica Enzymatica AB: Enzymatica tecknar låneavtal med huvudägare Pressreleaser Ladda ner | Visa Stäng
2022-04-28 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) on 28 April 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) den 28 april 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Interim report Q1/2022: Our financial targets remain in place Rapporter Ladda ner | Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Kvartalsrapport Q1/2022: Våra finansiella mål ligger fast Rapporter Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Article about ColdZyme acquitted from suspicions of research misconduct Pressreleaser Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Artikel om ColdZyme-studie frias från misstankar om oredlighet i forskning Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymatica's mouth spray to be launched in Turkey Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymaticas munspray lanseras i Turkiet Pressreleaser Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-03-28 Enzymatica Notice of Annual General Meeting 2022 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Enzymatica Kallelse till årsstämma 2022 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

17 Feb 2023 | Bokslutskommuniké 2022
27 Apr 2023 | Kvartalsrapport 2023-Q1
4 May 2023 | Årsstämma 2022
18 Jul 2023 | Kvartalsrapport 2023-Q2
7 Nov 2023 | Kvartalsrapport 2023-Q3